Chimerix, a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, says Michael Rogers has joined the company as Chief Development Officer.
Rogers will be responsible for overseeing chemistry, manufacturing, toxicology and project management as well as the advancement of compounds from the Chimerix Chemical Library.
He was formerly Chief Development Officer at Pharmasset, a pioneer in the use of nucleotide analogs for the treatment of Hepatitis C virus (HCV), until its acquisition by Gilead Sciences in January 2012. During his five years at Pharmasset, he was responsible for development, regulatory and portfolio management activities.
Prior to joining Pharmasset, Rogers held several positions in antiviral discovery and development at GlaxoSmithKline, including serving as Vice President, Division of Viral Diseases. In addition, he has led numerous anti-infective projects that resulted in successful commercialisation.
